| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5869100 | CONCORDIA PHARMS INC | Extended release clonidine formulation (tablet) |
Oct, 2013
(10 years ago) | |
Kapvay is owned by Concordia Pharms Inc.
Kapvay contains Clonidine Hydrochloride.
Kapvay has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Kapvay are:
- US5869100
Kapvay was authorised for market use on 30 September, 2009.
Kapvay is available in tablet, extended release;oral dosage forms.
The generics of Kapvay are possible to be released after 20 November, 2017.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-149) | Nov 20, 2017 |
| New Product(NP) | Sep 28, 2013 |
Drugs and Companies using CLONIDINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 September, 2009
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
How can I launch a generic of KAPVAY before it's drug patent expiration?
More Information on Dosage
KAPVAY family patents
